"CD47 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A ubiquitously expressed membrane glycoprotein. It interacts with a variety of INTEGRINS and mediates responses to EXTRACELLULAR MATRIX PROTEINS.
| Descriptor ID |
D051928
|
| MeSH Number(s) |
D12.776.395.550.014 D12.776.543.550.147
|
| Concept/Terms |
CD47 Antigen- CD47 Antigen
- Antigen, CD47
- CD47 Antigens
- IAP-50 Antigen
- Antigen, IAP-50
- IAP 50 Antigen
- Antigens, CD47
- Thrombospondin-1 Receptor CD47
- CD47, Thrombospondin-1 Receptor
- Integrin-Associated Protein p50
- Integrin Associated Protein p50
|
Below are MeSH descriptors whose meaning is more general than "CD47 Antigen".
Below are MeSH descriptors whose meaning is more specific than "CD47 Antigen".
This graph shows the total number of publications written about "CD47 Antigen" by people in this website by year, and whether "CD47 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 2 | 0 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 2 | 0 | 2 |
| 2022 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "CD47 Antigen" by people in Profiles.
-
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. Leuk Lymphoma. 2024 Jun; 65(6):864-867.
-
Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. Ann Hematol. 2022 Mar; 101(3):557-569.
-
Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells. Nat Commun. 2020 09 14; 11(1):4591.
-
Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling. J Exp Med. 2020 05 04; 217(5).
-
Impact of Novel Monoclonal Antibody Therapeutics on Blood Bank Pretransfusion Testing. Hematol Oncol Clin North Am. 2019 10; 33(5):797-811.
-
Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein a Signaling. Immunity. 2017 08 15; 47(2):363-373.e5.
-
MYC - a thorn in the side of cancer immunity. Cell Res. 2016 06; 26(6):639-40.
-
CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med. 2015 Oct; 21(10):1209-15.
-
"Velcro" engineering of high affinity CD47 ectodomain as signal regulatory protein a (SIRPa) antagonists that enhance antibody-dependent cellular phagocytosis. J Biol Chem. 2015 May 15; 290(20):12650-63.
-
Preemptive Tolerogenic Delivery of Donor Antigens for Permanent Allogeneic Islet Graft Protection. Cell Transplant. 2015; 24(6):1155-65.